- Home
- PBFS vs CTNM Comparison
PBFS vs CTNM Comparison
Compare PBFS & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | PBFS | CTNM |
|---|---|---|
| Founded | 1889 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 329.3M | 328.1M |
| IPO Year | N/A | 2024 |
Fundamental Metrics
Financial Performance| Metric | PBFS | CTNM |
|---|---|---|
| Price | $14.73 | $11.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 12.4K | ★ 254.5K |
| Earning Date | 01-29-2026 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 16.64 | N/A |
| EPS | ★ 0.84 | N/A |
| Revenue | ★ $91,717,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.52 | ★ N/A |
| Revenue Growth | ★ 17.04 | N/A |
| 52 Week Low | $10.60 | $3.35 |
| 52 Week High | $14.93 | $15.25 |
Technical Indicators
Market Signals| Indicator | PBFS | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 79.03 | 50.46 |
| Support Level | $13.05 | $10.42 |
| Resistance Level | $13.49 | $13.48 |
| Average True Range (ATR) | 0.25 | 0.73 |
| MACD | 0.13 | 0.13 |
| Stochastic Oscillator | 90.69 | 39.91 |
Price Performance
Historical ComparisonAbout PBFS Pioneer Bancorp Inc.
Pioneer Bancorp Inc is involved in providing banking services. These services include Personal services such as Checking, Savings, eBanking Cards, and Business services such as Business Deposit and operating Accounts, Business eBanking, and Business loans. Some of the other services of the company include Government Banking, Wealth Management, Benefits Consulting and Insurance.
About CTNM Contineum Therapeutics Inc.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.